source
- Rapport Therapeutics reports Phase 2 success for J&J-licensed bipolar mania drugRapport Therapeutics announced that its oral investigational drug, which modulates AMPA receptors, has successfully completed a Phase 2 trial in patients with bipolar mania. The study met its prim…
- Exclusive: Astellas partners with Boston ‘miniproteins’ startupChris Bahl believes AI can help make tiny proteins capable of doing things that bigger and more traditional proteins like antibodies struggle to do. And now the Japanese drugmaker Astellas is buyin…Endpoints · 1h ago↗ source